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Conclusions: HSA is a useful method for detecting 
uncorrectable dose deviations derived from a clear clinical 
motivation. As such, it is a promising method for detecting 
deviations relevant to real-time dosimetry. However, the 
current number of false alerts is still too high for direct 
clinical implementation.  
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Purpose/Objective: Entrance dose in vivo dosimetry (IVD) 
using diodes is an end-to-end QA procedure that is widely 
used in conventional radiotherapy treatments. However, in 
advanced delivery techniques, such as SIB-IMRT, the 
reliability of this QA procedure is controversial. We 
developed a reliable QA procedure for breast treatments 
delivered using a SIB-IMRT technique based on IVD using 
diodes. 
Materials and Methods: We calibrated 6-12 MV QED diodes 
(Sun Nuclear) using an emX electrometer (IBA) in terms of 
entrance dose at SSD = 90 cm and field size = 10 cm x 20 cm 
(average conditions for IMRT breast treatments). We 
measured correction factors for distance, field size, 
obliquity, and MLC transmission. We planned 14 SIB breast 
treatments using 6MV x-rays and 7-9 sliding window IMRT 
fields (TPS: Eclipse, algorithm: AAA v8.9; Varian). 
Determining entrance dose points is challenging due to 
fluence modulation, and also to patient contour 
irregularities, beam obliquity and tissue heterogeneities. To 
minimize these challenges, we calculated all treatment fields 
at 0º gantry angle, maintaining the SSD, on a regular water 
phantom. For each field, we recorded entrance dose (at 
maximum dose depth) at two points: on the central axis and 
on the region of highest fluence. Treatments were performed 
using a Clinac 2100C/D equipped with a Millenium 120 MLC 
and the RPM system (Varian) for respiratory motion 
management. We placed one diode at each of the 
aforementioned points on the patients' skin. We assessed 
clinical uncertainties by placing the diodes at the same 
position but on a Plastic Water phantom (CIRS), and 
irradiating them under the conditions used for entrance dose 
calculations. To ensure positioning accuracy was lower than 
0.5 cm, we attached a template which projected a 1 cm 
square grid at isocenter to the collimator using an add-on. 
We compared IVD measurements with the calculated 
entrance doses. 
Results: The table shows the average difference between 
measurements and calculations, excluding doses below fixed 
thresholds. Consistency improved by increasing the threshold 
because we excluded false positives due to non-significant 
dose contributions. Although agreement between in-phantom 
measurements and calculations was excellent, in patients we 
observed larger differences and variability due to positioning 
inaccuracies (figure). The table shows the two-fold 
tolerances which provided >95% of acceptable IVD 
assessments. 
 
 
 
 
Conclusions: IVD using diodes is a feasible QA procedure for 
breast treatments delivered using a SIB-IMRT technique. We 
propose using two diodes per field in high-fluence regions 
(entrance dose >0.2 Gy). We suggest a two-fold tolerance for 
IVD assessment (95% confidence limits): a dose difference of 
15% for both diodes per field, and an average difference of 
3.6% including all measurements per patient. 
This work was funded by grant Barcelona Board of the 
Spanish Association Against Cancer (AECC) 2012. 
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Purpose/Objective: A co-ordinated research project (CRP) is 
under development and implementation within a 
collaborative multi-centre effort. The aim of the CRP is to 
broaden the portfolio of dosimetry audits offered to 
radiotherapy centres by national audit networks operating in 
middle and low income countries. Moreover, the inclusion of 
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audits of more advanced radiotherapy technologies such as 
IMRT is timely since they are becoming increasingly used for 
cancer treatment across the world.  
Materials and Methods: The CRP has developed new 
methodologies for four audit steps: (i) remote verification of 
TPS calculation of small beam output factors (ii) dosimetry 
audit of MLC positional performance for IMRT using 
radiochromic film, (iii) film audit of single clinical IMRT field 
dose delivery and (iv) ‘end-to-end’ dosimetry audit (imaging, 
planning, dose delivery) for multiple field IMRT techniques 
using TLDs and radiochromic films. New procedures and 
phantoms as well as instructions and data sheets for audited 
centres have been developed and are being tested through 
multinational pilot studies. The CRP has brought together 
research groups from 14 countries across the world. 
Results: The first CRP study developed and tested procedures 
for the audit of small beam output of high energy photon 
beams relevant for IMRT treatment planning. TPS calculated 
beam outputs were compared to the published reference 
data sets. The results show good agreement (within 1%) 
between the TPS output and the reference data for field 
sizes ≥ 4 × 4 cm2 but dose overestimation by TPSs by 2%-3% 
for field sizes ≤ 3 × 3 cm2. The second step evaluated MLC 
performance using picket fence tests and revealed that most 
audited MLCs perform as expected. The third step involved a 
comparison of gamma analysis techniques. This included a 
multicentre analysis of a single film irradiated with a 
complex field arrangement, which highlighted differences in 
gamma agreement attributable to the differences in film 
scanners and calculation algorithms employed in gamma 
analysis software. This test also included irradiation and 
analysis of a complex clinical field by each institution. Most 
results available to-date show good agreement between the 
TPS plans prepared by the participants and the dose 
distributions delivered to the films. The fourth step ‘end-to-
end’ IMRT audit is on-going. 
Conclusions: A four step methodology for remote dose audits 
for advanced radiotherapy dose delivery relevant to IMRT has 
been developed, and following the successful testing, is being 
made available. The CRP results thus far indicate challenges 
in TPS commissioning for small field sizes, and challenges for 
multicentre comparison of gamma analysis for complex dose 
distributions. 
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Purpose/Objective: The purpose of the present study is to do 
a retrospective analysis of the percentage-gamma-pass (%GP) 
values obtained from a large dataset of Tomotherapy pre-
treatment Quality Assurance (QA) to determine which are the 
pathologies and planning parameters more susceptible of 
producing poorer QA results. 
Materials and Methods: 384 Helical Tomotherapy (HT) pre-
patient QA were considered. For each plan, treated 
pathology and planning parameters ( field width (FW), pitch, 
modulation factor (MF), number of sinogram segments, 
calculation grid, gantry period, total treatment time, couch 
travel distance, fraction dose, simultaneous boost technique) 
have been reported. The 3D diode array ArcCHECK™ and 
3%/3mm , both with local and global normalization, gamma 
index metric has been used to perform comparison between 
measured and planned dose distributions. 
Results: We obtained an average %GP equal to (96.1±4.4), 
(92.5±7.5) and (96.9±4.7) for the %GP evaluated by using 
global and local with two dose difference threshold (DDT) 
equal to 3 and 5 cGy, respectively. The results of our analysis 
showed that %GP results depend, on one hand, on the GI 
calculation method, and, on the other hand, on the treated 
pathologies, which have different treatment planning 
parameters, dose prescriptions and extensions of irradiated 
volumes. In particular, a statistical dependence with 
irradiated length, maximum dose to diodes, dose per fraction 
and pitch was observed. Correlation Coefficient (CC) and p-
value (P) for the significance of the correlation between 
global and local %GP with DDT equal to 3 and 5 cGy and 
planning parameters are shown in the following table. 
 
  
Conclusions: Tomotherapy QA can generally achieve %GP 
higher than 90%. Attention should be paid when performing 
pre-treatment QA of plans with large pitch value, long 
irradiated volumes, high dose regions that falls on the 
ArcCheck’s diodes and high doses per fraction, because they 
are more susceptible of having a lower %GP. Nevertheless, 
%GP is independent on modulation factor.  
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Purpose/Objective: The 30-μm thick sensitive layer of EBT2 
film is coated onto a 175-μm thick polyester substrate while 
the overlaminate features a thickness of a mere 75 μm, 
consisting of 25-μm adhesive and 50-μm polyester. In 
literature, this asymmetric construction has been criticized 
as it introduces an extra dependence of the upside-down 
